Tags

Type your tag names separated by a space and hit enter

Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Handb Exp Pharmacol. 2015; 231:233-59.HE

Abstract

This review focuses on the role of the endocannabinoid signaling system in controlling neuronal survival, an extremely important issue to be considered when developing new therapies for neurodegenerative disorders. First, we will describe the cellular and molecular mechanisms, and the signaling pathways, underlying these neuroprotective properties, including the control of glutamate homeostasis, calcium influx, the toxicity of reactive oxygen species, glial activation and other inflammatory events; and the induction of autophagy. We will then concentrate on the preclinical studies and the few clinical trials that have been carried out targeting endocannabinoid signaling in three important chronic progressive neurodegenerative disorders (Parkinson's disease, Huntington's chorea, and Alzheimer's disease), as well as in other less well-studied disorders. We will end by offering some ideas and proposals for future research that should be carried out to optimize endocannabinoid-based treatments for these disorders. Such studies will strengthen the possibility that these therapies will be investigated in the clinical scenario and licensed for their use in specific disorders.

Authors+Show Affiliations

Facultad de Medicina, Departamento de Bioquímica y Biología Molecular III, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Ciudad Universitaria s/n, 28040, Madrid, Spain. jjfr@med.ucm.es. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. jjfr@med.ucm.es. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. jjfr@med.ucm.es.Laboratorio de Apoyo a la Investigación, Hospital Universitario Fundación Alcorcón, Madrid, Spain. Departamento de Ciencias Biosanitarias, Universidad Francisco de Vitoria, Madrid, Spain.Facultad de Medicina, Departamento de Bioquímica y Biología Molecular III, Instituto Universitario de Investigación en Neuroquímica, Universidad Complutense, Ciudad Universitaria s/n, 28040, Madrid, Spain. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26408163

Citation

Fernández-Ruiz, Javier, et al. "Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others." Handbook of Experimental Pharmacology, vol. 231, 2015, pp. 233-59.
Fernández-Ruiz J, Romero J, Ramos JA. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others. Handb Exp Pharmacol. 2015;231:233-59.
Fernández-Ruiz, J., Romero, J., & Ramos, J. A. (2015). Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others. Handbook of Experimental Pharmacology, 231, 233-59. https://doi.org/10.1007/978-3-319-20825-1_8
Fernández-Ruiz J, Romero J, Ramos JA. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others. Handb Exp Pharmacol. 2015;231:233-59. PubMed PMID: 26408163.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others. AU - Fernández-Ruiz,Javier, AU - Romero,Julián, AU - Ramos,José A, PY - 2015/9/27/entrez PY - 2015/9/27/pubmed PY - 2015/12/19/medline KW - Alzheimer’s disease KW - Cannabinoids KW - Endocannabinoids KW - Huntington’s disease KW - Neurodegeneration KW - Neuroprotection KW - Parkinson’s disease SP - 233 EP - 59 JF - Handbook of experimental pharmacology JO - Handb Exp Pharmacol VL - 231 N2 - This review focuses on the role of the endocannabinoid signaling system in controlling neuronal survival, an extremely important issue to be considered when developing new therapies for neurodegenerative disorders. First, we will describe the cellular and molecular mechanisms, and the signaling pathways, underlying these neuroprotective properties, including the control of glutamate homeostasis, calcium influx, the toxicity of reactive oxygen species, glial activation and other inflammatory events; and the induction of autophagy. We will then concentrate on the preclinical studies and the few clinical trials that have been carried out targeting endocannabinoid signaling in three important chronic progressive neurodegenerative disorders (Parkinson's disease, Huntington's chorea, and Alzheimer's disease), as well as in other less well-studied disorders. We will end by offering some ideas and proposals for future research that should be carried out to optimize endocannabinoid-based treatments for these disorders. Such studies will strengthen the possibility that these therapies will be investigated in the clinical scenario and licensed for their use in specific disorders. SN - 0171-2004 UR - https://www.unboundmedicine.com/medline/citation/26408163/Endocannabinoids_and_Neurodegenerative_Disorders:_Parkinson's_Disease_Huntington's_Chorea_Alzheimer's_Disease_and_Others_ L2 - https://dx.doi.org/10.1007/978-3-319-20825-1_8 DB - PRIME DP - Unbound Medicine ER -